LSL/MED/0246 The Supply of Tranexamic Acid Auto-Injector (TXA AI)
Description: LSL/MED/0246 Procurement description Provide sufficient information to understand the scope of the procurement. In April 2015 the MOD signed a thirteen year contract with Leidos Europe Ltd to provide the procurement and inventory management of commodity items (as well as the storage and distribution services) historically provided in-house by the Logistic Commodities and Services Operating Centre. Leidos, working with the MOD, will transform the way these services are delivered to ensure requirements continue to be met whilst providing best value for money for the department. The organisation delivering these services is known as Team Leidos. Team Leidos would like to make markets aware that we are intending to investigate innovative approaches to fill our Supply of Tranexamic Acid Auto-Injector (TXA AI) requirements. We are actively seeking innovative, commercially (read more...)
Summary: The procurement process for the supply of Tranexamic Acid Auto-Injector (TXA AI) is currently in the planning stage, managed by Leidos Supply Limited, a central government authority based in Bristol, United Kingdom. The procurement is intended to source innovative, commercially viable solutions for an auto-injector device containing 1g of Tranexamic Acid in no greater than 3ml volume. The estimated framework value falls between £4,000,000 and £5,000,000. A preliminary market engagement notice (PMEN) has been issued to understand market innovations and inform future strategies. The deadline for submitting PMEN documents is set for 27 July 2026, with further procurement notifications anticipated by 16 November 2026. Delivery is expected across the United Kingdom for various medicinal products under the main procurement category of goods. The planned contract period spans from 21 May 2027 to 20 May 2031.